Article thumbnail

Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study

By Sarah Djabarouti, Dominique Breilh, Pierre Duffau, Estibaliz Lazaro, Carine Greib, Olivier Caubet, Marie-Claude Saux, Jean-Luc Pellegrin and Jean-François Viallard
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2010). Amoura Z: Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum
  2. (2008). Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune diseases on mycophenolate mofetil. Nephrol Dial Transplant
  3. (2001). B: In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther Drug Monit
  4. (2009). Breilh D: Measurement of total and unbound mycophenolic acid and its glucuronide by liquid chromatography coupled with mass spectrometry. Application to pharmacokinetic study of mycophenolate mofetil in patients with autoimmune diseases. Chromatographia
  5. (1991). Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum
  6. (2009). DW: Therapeutic monitoring of mycophenolate in transplantation: is it justified? Curr Drug Metab
  7. (2007). Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcome after renal transplantation.
  8. (2009). MH: Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. Lupus
  9. (2009). Moder KG: Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus. Lupus
  10. (2009). Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. Lupus
  11. (2007). Tett SE: Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet
  12. (1994). Urowitz MB: Serologically active clinically quiescent systemic lupus erythematosus-predictors of clinical flares.